よむ、つかう、まなぶ。
10参考資料１－２ 成人用肺炎球菌ワクチンファクトシート［4.9MB］ (41 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_70339.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会（第64回 2／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory
Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4):
109-17.
115.
Kishino H, Sawata M, Igarashi R, et al. Safety and Immunogenicity of V114, a 15-valent
Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese
Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE). Jpn J Infect Dis
2022; 75(6): 575-82.
116.
Hurley D, Griffin C, Young M, et al. Safety, Tolerability, and Immunogenicity of a 20-Valent
Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis 2021; 73(7):
e1489-e97.
117.
Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the
immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccinenaive adults 18 through 49 years of age. Vaccine 2021; 39(38): 5428-35.
118.
Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety,
Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Clin Infect Dis 2022; 75(3): 390-8.
119.
Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent
pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal
vaccination. Vaccine 2021; 39(51): 7494-502.
120.
Haranaka M, Young Song J, Huang KC, et al. A phase 3 randomized trial of the safety and
immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South
Korea, and Taiwan. Vaccine 2024; 42(5): 1071-7.
121.
大石和徳, 大島信治, 川上和義, 川上健司, 永井英明, 渡辺彰. 肺炎球菌ワクチン再接種のガイダン
ス （改訂版）. 感染症学雑誌 2017; 91(4): 543-52.
122.
Kawakami K, Kishino H, Kanazu S, et al. Revaccination with 23-valent pneumococcal polysaccharide
vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine 2016; 34(33): 3875-81.
123.
Song JY, Chang CJ, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent
pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years:
A randomized phase III trial (PNEU-PATH). Vaccine 2021; 39(43): 6422-36.
124.
Hammitt LL, Quinn D, Janczewska E, et al. Phase 3 trial to evaluate the safety, tolerability, and
immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal
polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis
by baseline risk factors. Hum Vaccin Immunother 2023; 19(1): 2177066.
125.
Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent
pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal
responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31(35):
3594-602.
126.
Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal
41
Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71(4):
109-17.
115.
Kishino H, Sawata M, Igarashi R, et al. Safety and Immunogenicity of V114, a 15-valent
Pneumococcal Conjugate Vaccine, Compared with 13-valent Pneumococcal Conjugate Vaccine in Japanese
Adults Aged ≥65 Years: Subgroup Analysis of a Randomized Phase III Trial (PNEU-AGE). Jpn J Infect Dis
2022; 75(6): 575-82.
116.
Hurley D, Griffin C, Young M, et al. Safety, Tolerability, and Immunogenicity of a 20-Valent
Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age. Clin Infect Dis 2021; 73(7):
e1489-e97.
117.
Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the
immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccinenaive adults 18 through 49 years of age. Vaccine 2021; 39(38): 5428-35.
118.
Essink B, Sabharwal C, Cannon K, et al. Pivotal Phase 3 Randomized Clinical Trial of the Safety,
Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years.
Clin Infect Dis 2022; 75(3): 390-8.
119.
Cannon K, Elder C, Young M, et al. A trial to evaluate the safety and immunogenicity of a 20-valent
pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal
vaccination. Vaccine 2021; 39(51): 7494-502.
120.
Haranaka M, Young Song J, Huang KC, et al. A phase 3 randomized trial of the safety and
immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South
Korea, and Taiwan. Vaccine 2024; 42(5): 1071-7.
121.
大石和徳, 大島信治, 川上和義, 川上健司, 永井英明, 渡辺彰. 肺炎球菌ワクチン再接種のガイダン
ス （改訂版）. 感染症学雑誌 2017; 91(4): 543-52.
122.
Kawakami K, Kishino H, Kanazu S, et al. Revaccination with 23-valent pneumococcal polysaccharide
vaccine in the Japanese elderly is well tolerated and elicits immune responses. Vaccine 2016; 34(33): 3875-81.
123.
Song JY, Chang CJ, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent
pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years:
A randomized phase III trial (PNEU-PATH). Vaccine 2021; 39(43): 6422-36.
124.
Hammitt LL, Quinn D, Janczewska E, et al. Phase 3 trial to evaluate the safety, tolerability, and
immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal
polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis
by baseline risk factors. Hum Vaccin Immunother 2023; 19(1): 2177066.
125.
Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent
pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal
responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013; 31(35):
3594-602.
126.
Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal
41